

LIST OF FIGURES

Section	Description	Page No.
1.	Introduction.....	
1.1	Chemical structures of SCFAs.....	5
1.2	TLRs and NLRs cross-talk in pathogenesis of type 2 diabetes.....	13
2.	Review of Literature.....	
2.1	Diversity and distribution of the gastrointestinal microflora.....	21
2.2	Overview of the long term and short term impact of dietary fibers on the intestinal microbiome and metabolome.....	29
2.3	SCFAs and inter organ cross talk.....	33
2.4	TLRs and NLRs signalling pathways.....	38
2.5	Obesity mediated development of inflammation and insulin resistance.....	40
4.	Results and Discussion.....	
	Objective 1.....	
4.1	Effect of spectrum specific antibiotics and chitosan administration on physiological parameters.....	76
4.2	Effect on OGTT after 12 weeks of the experimental period.....	77
4.3	Implication of gut microflora alteration on blood biochemical parameters.....	78
4.4	Effect of gut microflora modulation on hepatic inflammation markers.....	79
4.5	Consequences of gut microbiota modulation on inflammatory markers.....	80
4.6	Effect on liver biochemical parameters following gut microbiota alteration.....	81
4.7	PCR confirmation of the isolated bacterial DNA from standard	82

	bacterial strains.....	
4.8	Effect of gut microflora alteration on gut dominant phyla.....	83
4.9	Effect of gut microflora alteration on gut dominant genera.....	85
4.10	Effect of gut microflora alteration on short chain fatty acids (SCFAs)	87
4.11	Effect of gut microbiota modulation on BSH producing bacterial copy numbers.....	88
4.12	Effect of gut microflora alteration on adipose tissue histopathology...	89
4.13	Effect of gut microflora alteration on TLRs expression.....	90
4.14	Effect of gut microflora alteration on NLRs expression.....	91
4.15	Effect of gut microflora alteration on inflammatory gene expression..	93
4.16	Effect of gut microflora alteration on G-protein coupled receptor (GPCR) and insulinotropic modulation.....	95
4.17	The role of GPCRs, GLP-1, DPP-4 and GLUT4 in the glucose homeostasis.....	103
<hr/>		
	Objective 2.....	
<hr/>		
4.18	FT-IR spectra of the drugs, polymers and microspheres.....	108
4.19	Cumulative drug release study from enteric coated cefdinir microspheres from the optimized batches.....	111
4.20	Cumulative drug release study from enteric coated linezolid microspheres from the optimized batches.....	116
4.21	Scanning electron microscopy (SEM).....	118
4.22	<i>In vitro</i> antimicrobial activity of enteric coated microspheres.....	118
4.23	Ex-vivo antimicrobial analysis.....	120
<hr/>		
	Objective 3.....	
<hr/>		
4.24	Effect on oral glucose tolerance test (OGTT) assay.....	128
4.25	Effect on gut dominant bacterial phyla.....	132
4.26	Effect on gut dominant bacterial genera.....	134
4.27	Effect of on short chain fatty acids (SCFAs).....	137
4.28	Effect on TLRs expression.....	138
4.29	Effect of on NLRs expression.....	139

4.30	Effect of on inflammatory gene expression.....	141
4.31	Effect on SCFA receptor and insulinotropic modulators.....	143
4.32	Effect of adipokines expression.....	144
4.33	Effect on PPARs expression.....	145
4.34	Mechanism of PPARs for regulation of insulin sensitivity.....	155
